CritiTech Overview
- Year Founded
-
2001
- Status
-
Private
- Employees
-
18
- Latest Deal Type
-
2ndary - Private
- Investors
-
8
CritiTech General Information
Description
Manufacturer of particle compounds intended to micronize a wide variety of small-molecule and biotechnology drugs. The company's fine-particle compounds utilize its carbon dioxide technology to develop potent molecules, poorly soluble compounds and bio-molecules with its ability to simplify formulations, enabling pharmacists to develop and differentiate drugs and medical devices.
Contact Information
Website
www.crititech.comCorporate Office
- 1849 East 1450 Road
- PO Box 442280
- Lawrence, KS 66044
- United States
Corporate Office
- 1849 East 1450 Road
- PO Box 442280
- Lawrence, KS 66044
- United States
CritiTech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Secondary Transaction - Private | 10-Jul-2023 | Completed | Generating Revenue | |||
| 11. Debt - PPP | 29-Apr-2020 | Completed | Generating Revenue | |||
| 10. Later Stage VC | 01-Apr-2019 | Completed | Generating Revenue | |||
| 9. Later Stage VC | 21-Aug-2014 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 14-Feb-2013 | Completed | Generating Revenue | |||
| 7. Angel (individual) | 31-Dec-2010 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 10-Dec-2009 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 02-Dec-2008 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 15-Feb-2005 | $480K | $480K | Completed | Generating Revenue | |
| 3. Grant | 04-Aug-2004 | $100K | Completed | Generating Revenue |
CritiTech Patents
CritiTech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4608414-A2 | Cisplatin particles and uses thereof | Pending | 25-Oct-2022 | ||
| EP-4608414-A4 | Cisplatin particles and uses thereof | Pending | 25-Oct-2022 | ||
| US-20240156861-A1 | Cisplatin particles and uses thereof | Pending | 25-Oct-2022 | ||
| WO-2024091869-A2 | Cisplatin particles and uses thereof | Inactive | 25-Oct-2022 | ||
| WO-2024091869-A3 | Cisplatin particles and uses thereof | Inactive | 25-Oct-2022 | A61K9/10 |
CritiTech Signals
CritiTech Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Accelerate Venture Partners | Angel Group | Minority | ||
| Angel (individual) | Minority | |||
| eGrowth Ventures | Not-For-Profit Venture Capital | Minority | ||
| KTECH Capital | PE/Buyout | Minority | ||
| Precede Fund | Venture Capital | Minority |
CritiTech Investments (2)
CritiTech’s most recent deal was a Corporate with NanOlogy (Pharmaceutical) for . The deal was made on 01-Jan-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| NanOlogy (Pharmaceutical) | 01-Jan-2017 | Corporate | Drug Discovery | ||
| NanOlogy (Pharmaceutical) | 01-Jan-2015 | Joint Venture | Drug Discovery |
CritiTech FAQs
-
When was CritiTech founded?
CritiTech was founded in 2001.
-
Where is CritiTech headquartered?
CritiTech is headquartered in Lawrence, KS.
-
What is the size of CritiTech?
CritiTech has 18 total employees.
-
What industry is CritiTech in?
CritiTech’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is CritiTech a private or public company?
CritiTech is a Private company.
-
What is CritiTech’s current revenue?
The current revenue for CritiTech is .
-
How much funding has CritiTech raised over time?
CritiTech has raised $18.3M.
-
Who are CritiTech’s investors?
Accelerate Venture Partners, , eGrowth Ventures, KTECH Capital, and Precede Fund are 5 of 8 investors who have invested in CritiTech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process